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Feasibility of Systematic Handgrip Strength Testing in
Digestive Cancer Patients Treated With Chemotherapy: The
FIGHTDIGO Study
Marie-Amelie Ordan, MD 1; Camille Mazza1; Coralie Barbe, MD2; Marine Perrier1; Damien Botsen1; Yohann Renard, MD3;
Johanna Moreau1; Mathilde Brasseur, MD1,2; Barbara Taillie`re, MD4; Eric Bertin, MD, PhD5; and Olivier Bouche, MD, PhD1,6
BACKGROUND: Handgrip strength (HGS) is a widely studied noninvasive test. Weak strength (dynapenia) seems to be associated
with high morbidity and mortality in different populations, notably oncology populations. Despite this, HGS testing is not used in daily
practice in oncology. The study was aimed at evaluating the feasibility and acceptability of HGS testing in patients with digestive can-
cer treated with ambulatory chemotherapy. METHODS: In this prospective, single-center study, enrolled patients were followed for 6
months. Two consecutive bilateral measures were performed with a Jamar dynamometer during each patient’s appointments in the
unit for intravenous treatment. A questionnaire was completed by patients and medical team members. RESULTS: There were 203
consecutive patients, and 201 were recruited. In all, 1704 of 1716 measurements (99.3%) were performed, and 201 patients (99.0%)
performed at least 1 measure; 190 (94.5%) performed all expected measures. One hundred sixty-four of 171 participating
patients (95.9%) found the test easy to perform, and 167 (97.7%) did not find the test restrictive. All of the 14 medical team members
found the test easy to perform, unrestrictive, and undisruptive in their daily practice. CONCLUSIONS: HGS testing is routinely
feasible, inexpensive, and well accepted by patients and medical teams in an ambulatory digestive cancer unit. Cancer 2018;124:1501-
6. VC 2017 American Cancer Society.
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INTRODUCTION
Cancer and malnutrition became major concerns in developed and developing countries during the last century.1,2 Diges-
tive cancers are particularly represented by bowel, stomach, and liver tumors, which are among the 10 most frequently
diagnosed cancers.2
In this specific population, malnutrition is commonly found, and it is a concern with approximately 39% of colorec-
tal cancers, 44% of esophageal and/or stomach cancers, and 67% of pancreatic cancers.3 It is responsible for higher mor-
bidity and mortality rates, and this explains why its screening and treatment are important.
The current definition of malnutrition relies on a low body mass index, unintentional weight loss, and/or hypoalbu-
minemia without inflammatory syndrome.4 Those 3 criteria do not totally reflect the complex physiopathology of malnu-
trition and its impact.
For many years, investigations have been performed in the area of malnutrition, and more attention has been paid to
muscle mass loss, which occurs in 80% of patients with cancer and is a first step toward malnutrition.5 However, muscle
mass alone cannot be interpreted without its function, that is, muscle strength.
The evaluation of muscle strength with a handgrip dynamometer has been widely studied. Strength physiologically
declines with age.6-8 Weak strength, known as dynapenia,9 is known to predict the risk of mortality from all causes when
it is measured in middle-aged individuals in the general population.6 Dynapenia also appears to be a factor in disability,10
nosocomial infections,11 and the length of hospital stays12 for elderly people. In oncology, low handgrip strength (HGS)
is associated with cancer-related fatigue,13 poor quality of life,14 postoperative complications,15 and high mortality.16 It
was also recently included in the consensual definition of sarcopenia, which associates muscle mass loss and weak
strength.17
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The HGS test was recently studied in large popula-
tion samples including up to 140,000 patients,18-20 and
this suggests that it may be an easy test to perform.
Despite this, the HGS test is not part of daily medical
practice, notably in oncology, and the feasibility and
acceptability of measuring grip strength in different medi-
cal services have not been yet established.21
The main objective of the current study was to deter-
mine whether routinely measuring HGS would be feasible
for patients with digestive cancer treated with chemother-
apy in an ambulatory digestive cancer unit. The other
objectives were to evaluate the cost of this HGS test and
its acceptability to patients and medical teammembers.
MATERIALS AND METHODS
Study Design and Participants
This prospective, single-center study was conducted in the
Ambulatory Digestive Cancer Unit (Unit of Ambulatory
Medicine, Oncology, and Hematology) of the Reims
Teaching Hospital (University Hospital Center of Reims)
in France. The patients were recruited from May 18,
2016, to November 18, 2016, and were followed for 6x
months. They were asked to perform the HGS test at each
of their appointments in the unit for their treatment
(every week (eg, Gemcitabine), 2 weeks (eg, FOLFIRI-
NOX), or longer (eg, VP16) according to the chemother-
apy protocol). The measure could be performed before,
during, or after the beginning of the perfusion. The test
was conducted in the same way by a medical physician, a
resident, a medical school student, or a nurse.
Patients were included in the study if they were older
than 18 years and had a digestive cancer treated with cyto-
toxic chemotherapy and/or biotherapy in the unit. They
were excluded if they could not give their consent, did not
understand the test, had a neuromuscular disorder, and/or
had appointed a health care proxy.
Ethical Approval
Informed written consent was obtained for each patient
enrolled in the trial. The Feasibility of Systematic Hand-
grip Strength Testing and Short-Term Changes in Muscle
Strength in Digestive Cancer Patients Treated by Chemo-
therapy (FIGHTDIGO) study was approved by the ethics
committee (Committee for the Protection of Persons EST
I, Dijon, France; March 25, 2016) and was registered at
ClinicalTrials.gov (NCT02797197).
Statistical Analysis
Data were described with means and standard deviations
for quantitative variables and with numbers and
percentages for qualitative variables. All analyses were per-
formed with SAS 9.4 (SAS Institute, Inc, Cary, North
Carolina).
HGS Measurements
HGSwas measured with a Jamar hydraulic dynamometer.
Two dynamometers were available in the ambulatory
unit. There were 5 possible positions, and the handle posi-
tion used in this study was position 2. Every patient was
seated comfortably in a chair. The shoulder of the upper
limb holding the dynamometer was in an adduction posi-
tion, the elbow was flexed to 90 degrees, and the forearm
and wrist were in a neutral position. The other upper limb
was placed alongside the body and relaxed. During the
examination, verbal encouragement was given to the
patients to obtain their best score. Four measurements
were taken, and each one was supposed to last 3 seconds.
Patients had to perform the first 2 measurements in a row:
one with the dominant hand and the other with the non-
dominant hand. Then, a 1-minute break was taken before
the 2 measurements were repeated. The effective time
needed to take the 4 measurements was approximately 15
seconds plus the 1-minute break used to proceed to the
assessment of the side effects of the last treatment.
Primary Outcome
The feasibility of the HGS test was represented by the pro-
portion of patients who performed at least 1 HGS test
among all patients hospitalized in the unit for a digestive
cancer treatment.
Secondary Outcomes
The total number of HGSmeasurements for each patient,
the number of HGS measurements with respect to the
number of hospitalizations in the unit, the number of
patients who performed 100% of the HGS measure-
ments, the number of patients who performed 50% to
fewer than 100% of the HGS measurements, the number
of patients who performed fewer than 50% of the meas-
urements, and the mean number of measures per patient
were evaluated.
The acceptability of the HGS test was determined
initially with an anonymous questionnaire given to the
patients after 3 months of follow-up and then with an
anonymous questionnaire given to the medical team
members who participated in the study at the end of the
follow-up.
The HGS test cost was estimated as follows: cost
estimates per hydraulic dynamometer, cost per patient,
and cost per measurement. It was then compared with
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other malnutrition markers such as weight and the modi-
fied Glasgow Prognostic Score (mGPS), which associates
serum albuminemia and C-reactive protein.
RESULTS
Description of the Population
A total of 203 patients were consecutively hospitalized.
Two patients were not included: 1 patient did not want to
participate, and another patient was excluded because of
limited cognitive function. Finally, 201 patients were ana-
lyzed (117 men [58.2%] and 84 women [41.8%]). Table
1 shows the participants’ characteristics. The majority of
the participants were right-handed (186 of 201 [92.5%]).
Colorectal cancer was the most frequent (n5 103
[51.2%]). Sixty-nine percent of the patients came for an
appointment for metastatic tumor treatment.
Feasibility
Among the 203 hospitalized patients, 201 (99.0%) per-
formed at least 1 HGS test during the follow-up. A total
of 1716 hospitalizations, corresponding to 1716 expected
measurements, were registered. A total of 1704 measure-
ments were performed, and 12 (0.7%) were missing for
various reasons: 1 patient refused to perform the test on
an occasion, 1 measure was forgotten, 7 others were
missed because of time constraints, 1 was missed because
of hand pain due to arthrosis, and 2 were missed for
unknown reasons. Among the 201 patients, 190 (94.5%)
performed 100% of the excepted measures. Ten patients
(5.0%) missed 1 measure, and 1 patient (0.5%) missed 2
measures. The mean number of measures per patient was
8.56 4, with a maximum of 19 measures per patient.
Acceptability
A total of 171 patients (85.1%) completed the question-
naire after 3 months of follow-up (Table 2). Some
patients had already used the Jamar dynamometer before
the study (n5 11 [6.4%]): 4 used it with a nutritionist, 1
used it with a digestive surgeon for another study, 1 used
it with a medical physician at work, 1 used it during a
checkup with the department of social insurance, 3 used it
in our department for another study, and 1 used it for an
unknown reason. The majority of the patients found the
hand dynamometer easy to use (n5 164 [95.9%]). Diffi-
culties met by the other patients (n5 7 [4.1%]) included
the high weight of the instrument (n5 2 [28.5%]), the
size of the instrument (n5 1 [14.3%]), and articular pains
due to arthrosis (n5 3 [42.9%]). Almost all of the
patients found the test not restrictive and estimated that
their care quality was not altered (n5 167 [97.7%]).
During the study, 14 members of the medical team
performed the test (Table 3): 5 medical residents, 1 MD/
PhD, and 8 medical students. Only 1 (7.1%) had used it
in a nutrition department before the beginning of the
study, and Yes 3 (23.1%) and No 10 (76.9%) had heard
about it. None of them found the test difficult to perform
or restrictive. It did not disturb their daily medical prac-
tice or the quality of their provided care. All of them con-
sidered this test useful enough to perform routinely for
patients with digestive cancer.
Economic Evaluation
Two hydraulic dynamometers were bought for approxi-
mately e200 each; this corresponded to e1.99 per patient
(e400/201 patients) and e0.23 per measurement (e400/
1704 measurements). Six weighing scales were used
TABLE 1. Baseline Characteristics (n5201)
Characteristic Value
Age, mean6SD, y 65.56 10.8
Sex, No. (%)
Male 117 (58.2)
Female 84 (41.8)
Laterality, No. (%)
Right-hander 186 (92.5)
Left-hander 15 (7.5)
Past medical history, No. (%)
Neuropathy before chemotherapy 6 (3)
Neuropathy due to anterior chemotherapy 67 (33.3)
High blood pressure 73 (36.3)
Myocardial infarction 13 (6.5)
Stroke 4 (2)
Chronic obstructive pulmonary disease 3 (1.5)
Body mass index, mean6SD, kg/m2 25.065.1
Previous oncologic surgery, No. (%) 128 (63.7)
mGPS, No. (%)
0 99 (55.0)
1 68 (37.8)
2 13 (7.2)
G8 score, mean6SD 12.462.1
Primary tumor, No. (%)
Colon and rectum 103 (51.2)
Esophagus 8 (4.0)
Stomach 22 (10.9)
Cholangiocarcinoma 11 (5.5)
Pancreas 44 (21.9)
Small intestine 3 (1.5)
Neuroendocrine tumor 8 (4.0)
Adenocarcinoma, unknown primitive tumor 2 (1.0)
Stage, No. (%)
Local 40 (19.9)
Locally advanced 23 (11.4)
Metastatic 138 (68.7)
Type of treatment, No. (%)
Chemotherapy 147 (73.1)
Biotherapy 4 (2.0)
Chemotherapy and biotherapy 50 (24.9)
Abbreviations: mGPS, modified Glasgow Prognostic Score; SD, standard
deviation.
For mGPS, 180/201 patients were evaluated because 21 patients had no
CRP and/or albuminemia at baseline.
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during the study. Each one cost approximately e50. Both
C-reactive protein and serum albumin sampling cost e16
per sample, which corresponded to e27,264 for 1704 hos-
pitalizations. Therefore, the HGS evaluation was almost
the same price as the price of weighing patients and was
far less expensive than the mGPS evaluation.
DISCUSSION
To our knowledge, this study is the first to show that
HGS testing with a Jamar dynamometer is routinely feasi-
ble for oncology patients in an ambulatory unit.
We obtained a large number of measurements in a
short period of time without interfering with medical
care. Some patients had difficulties, which may have led
to underestimations of their muscle strength. The first
was articular pains due to arthrosis. This should be sys-
tematically considered before the test is performed.
Another issue raised by 1 patient was the size of the dyna-
mometer in comparison with her hand size. Position 2
was chosen on the handle of the dynamometer and is con-
sidered to be the most reliable of the 5 positions.22 In the
future, more attention should be paid, and position 1
should be preferred for people with small hands, as already
suggested in a previous study.22
Few patients knew the HGS test before the study,
and except for 1 patient who did not want to participate,
the test piqued their interest and held their attention. A
high degree of compliance and observance was observed
during the entire period of the study. Other studies using
the HGS test have mainly been vertical studies and have
tended to collect only 1 to 2 measures per patient.16,18,23-
25 In our study, patients had to do it every week or every 2
weeks, and despite this high frequency, 98.8% did not
find the test restrictive.
What was most surprising was the lack of knowledge
about sarcopenia, dynapenia, and HGS testing among the
medical staff. Only 1 medical student had used the Jamar
dynamometer in a previous study. This observation high-
lights the fact that improvements could be made to our
teaching in the area of malnutrition, especially because all
participants showed a real interest and found this test use-
ful enough to perform routinely in our population.
Another interesting aspect is the economic aspect
because measuring HGS is affordable in comparison with
an mGPS evaluation and costs almost the same as weigh-
ing patients. Hydraulic dynamometers are robust and can
be used for several years if the manufacturer’s recommen-
dations are respected (the calibration of every new
machine and annual or more frequent calibrations if the
instrument is used on a daily basis).
Although this test was designed to be used in a daily
medical and paramedical practice, nurses did not feel
able to perform it on patients. The main reason invoked
was a lack of time. The time needed to perform the HGS
test was not evaluated with a chronometer but was esti-
mated to be 2 minutes the first time (because of informa-
tion given to the patient) and less than 1 minute 20
seconds the other time. This low involvement consti-
tuted a major bias in our study. Further training of the
paramedical team seems fundamental to make them
aware of the importance of this issue and to familiarize
the team with the test.
TABLE 2. Patient Questionnaire
Question Answer No. (%)
Have you ever performed this test? Yes 11 (6.4)
No 160 (93.6)
If yes, with
A nutritionist 4 (36.4)
An endocrinologist 0
Your general practitioner 0
Other 7 (63.6)
Did you find this test difficult to perform? Yes 7 (4.1)
No 164 (95.9)
If yes, could you explain why?
The dynamometer was too heavy. 2 (28.5)
The dynamometer was difficult to handle. 4 (57.1)
Other 4 (57.1)
Did you find this test restrictive to perform at the hospital? Yes 2 (1.2)
No 167 (98.8)
After being informed about the purpose of this test,
did you pay attention to the result?
Yes 117 (69.2)
No 52 (30.8)
Did you feel that performing this test interfered
with the usual medical care?
Yes 2 (1.2)
No 167 97.7
For the last 3 questions, 2 patients did to answer.
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Another limit was the fact that, mainly because of
deaths before the third month of follow-up, question-
naires were not completed by all patients.
These results suggest that we can evaluate the
strength of patients at each of their appointments or every
time they are hospitalized in the same way that we weigh
them. It can be done, especially because the Jamar dyna-
mometer is an inexpensive, portable, and easy-to-use tool.
Nevertheless, several aspects of using the Jamar dyna-
mometer may require further investigation. First, although
more and more studies are attempting to determine cut
points for weak grip strength with respect to age, sex, and
ethnic group,8,17,20,25-29 the HGS dynamometer thresholds
remain undetermined for patients with cancer. Second, we
may need more standardization for the realization of the
test: the number of attempts needed,30 the hand chosen
(the dominant hand vs the nondominant hand), and the
value chosen (the best or mean of several values).22 Third,
the consensual definition of sarcopenia includes low muscle
mass, which suggests a computed tomography scan. How-
ever, a computed tomography scan is expensive, invasive,
and difficult to perform, especially if a whole population
requires screening. If muscle strength declines before mus-
cle mass loss and weight loss, as suggested by Norman
et al,14 sarcopenia might be detected if we look for dynape-
nia first. Malnutrition could, therefore, be treated earlier,
and its consequences could be limited. Further research
will be necessary to clarify this. Finally, the correlations
between dynapenia, chemotherapy toxicities, and other
prognostic markers in malnutrition, such as the mGPS,
body mass index, and performance status, are interesting
and are being currently studied.
In conclusion, measuring grip strength with the HGS
test is generally accepted, inexpensive, and feasible in routine
practice. The measurement of grip strength with the HGS
test presents minimal interference for both patients with
digestive cancer treated by ambulatory chemotherapy and
the medical professionals providing treatment. This study
suggests that this test could be a part of our daily practice
without affecting the quality of care or reducingmedical care
efficiencies. Further investigation is required to standardize
the measurement for patients with cancer. Correlations
between dynapenia and the performance status, nutritional
data, and chemotherapy toxicities are being evaluated.
TABLE 3. Medical Member Questionnaire
Question Answer No. (%)
Are you A man? 8 (57.1)
A woman? 6 (42.9)
How old are you? Younger than 35 y 13 (92.9)
Between 35 and 55 y 0
Older than 55 y 1 (7.1)
You are a PhD 1 (7.1)
Medicine resident 5 (35.7)
Medical student 8 (57.2)
Nurse 0
Have you ever performed this test? Yes 1 (7.1)
No 13 (92.9)
If no, have you ever heard about this test?
Yes 3 (23.1)
No 10 (76.9)
Did you find this test difficult to perform? Yes 0
No 14 (100)
If yes, could you explain why? 0 (0)
The dynamometer was too heavy. 0 (0)
The dynamometer was difficult to handle. 0 (0)
The way the test works was difficult to
explain to the patient.
0 (0)
Other 0 (0)
Did you find this test restrictive to perform at the hospital? Yes 0
No 14 (100)
Did you find that performing this test disturbed your daily practice? Yes 0
No 14 (100)
Did you feel that performing this test interfered with your usual medical care? Yes 0
No 14 (100)
Did you meet difficulties during the study process?a Yes 1 (7.1)
No 13 (92.9)
Do you think that we should use this test routinely in oncology? Yes 14 (100)
No 0
a A lack of time, difficulty with comprehending the dynamometer handle, and so forth.
Feasibility of Handgrip Strength/Ordan et al
Cancer April 1, 2018 1505
FUNDING SUPPORT
No specific funding was disclosed.
CONFLICT OF INTEREST DISCLOSURES
Camille Mazza reports personal fees from Pierre Fabre outside the
submitted work. Damien Botsen reports personal fees from Pierre
Fabre and nonfinancial support from GlaxoSmithKline, Chugai,
and Amgen outside the submitted work. Mathilde Brasseur reports
personal fees from Bayer and nonfinancial support from Pierre
Fabre, Novartis, Amgen, Roche, and AbbVie outside the submitted
work. Olivier Bouche reports grants and personal fees from Roche
and Pierre Fabre and personal fees from Amgen, Bayer, Lilly,
Merck, and Novartis outside the submitted work.
AUTHOR CONTRIBUTIONS
Marie-Amelie Ordan: Conceptualization, methodology, valida-
tion, and writing–original draft. Camille Mazza: Conceptualiza-
tion, investigation, validation, and writing—review and editing.
Coralie Barbe: Data curation, formal analysis, methodology, soft-
ware, supervision, validation, and writing—review and editing.
Marine Perrier: Conceptualization, investigation, validation, and
writing—review and editing. Damien Botsen: Conceptualization,
investigation, validation, and writing—review and editing. Yohann
Renard: Conceptualization, investigation, validation, and writ-
ing—review and editing. Johanna Moreau: Conceptualization,
investigation, validation, and writing—review and editing.
Mathilde Brasseur: Conceptualization, supervision, validation,
and writing–review and editing. Barbara Taillie`re: Conceptualiza-
tion, investigation, validation, and writing—review and editing.
Eric Bertin: Conceptualization, supervision, validation, and writ-
ing–review and editing.Olivier Bouche: Conceptualization, inves-
tigation, methodology, supervision, validation, and writing—
review and editing.
REFERENCES
1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and
mortality worldwide: sources, methods and major patterns in GLO-
BOCAN 2012. Int J Cancer. 2015;136:E359-E386.
2. World Health Organization. Cancer. http://www.who.int/mediacentre/
factsheets/fs297/en/. Accessed April 4, 2017
3. Hebuterne X, Lemarie E, Michallet M, de Montreuil CB, Schneider
SM, Goldwasser F. Prevalence of malnutrition and current use of
nutrition support in patients with cancer. J Parenter Enteral Nutr.
2014;38:196-204.
4. Haute Autorite de Sante. Strategie de priseen charge encas de
denutritionproteino-energetique chez la personnea^gee. https://www.has-
sante.fr/portail/jcms/c_546549/fr/strategie-de-prise-en-charge-en-cas-de-
denutrition-proteino-energetique-chez-la-personne-agee. Accessed
September 28, 2017.
5. Cohen S, Nathan JA, Goldberg AL. Muscle wasting in disease:
molecular mechanisms and promising therapies. Nat Rev Drug Dis-
cov. 2015;14:58-74.
6. Rantanen T, Harris T, Leveille SG, et al. Muscle strength and body
mass index as long-term predictors of mortality in initially healthy
men. J Gerontol A Biol Sci Med Sci. 2000;55:M168-M173.
7. Norman K, Stobaus N, Gonzalez MC, Schulzke JD, Pirlich M.
Hand grip strength: outcome predictor and marker of nutritional
status. Clin Nutr. 2011;30:135-142.
8. Dodds RM, Syddall HE, Cooper R, Kuh D, Cooper C, Sayer AA.
Global variation in grip strength: a systematic review and meta-
analysis of normative data. Age Ageing. 2016;45:209-216.
9. Clark BC, Manini TM. Sarcopenia5 /5 dynapenia. J Gerontol A
Biol Sci Med Sci. 2008;63:829-834.
10. Rantanen T, Guralnik JM, Foley D, et al. Midlife hand grip
strength as a predictor of old age disability. JAMA. 1999;281:558-
560.
11. Cosqueric G, Sebag A, Ducolombier C, Thomas C, Piette F, Weill-
Engerer S. Sarcopenia is predictive of nosocomial infection in care of
the elderly. Br J Nutr. 2006;96:895-901.
12. Kerr A, Syddall HE, Cooper C, Turner GF, Briggs RS, Sayer AA.
Does admission grip strength predict length of stay in hospitalised
older patients? Age Ageing. 2006;35:82-84.
13. Kilgour RD, Vigano A, Trutschnigg B, et al. Cancer-related fatigue:
the impact of skeletal muscle mass and strength in patients with
advanced cancer. J Cachexia Sarcopenia Muscle. 2010;1:177-185.
14. Norman K, Stobaus N, Smoliner C, et al. Determinants of hand
grip strength, knee extension strength and functional status in cancer
patients. Clin Nutr. 2010;29:586-591.
15. Chen CH, Ho-Chang, Huang YZ, Hung TT. Hand-grip strength is
a simple and effective outcome predictor in esophageal cancer fol-
lowing esophagectomy with reconstruction: a prospective study.
J Cardiothorac Surg. 2011;6:98.
16. Kilgour RD, Vigano A, Trutschnigg B, Lucar E, Borod M, Morais
JA. Handgrip strength predicts survival and is associated with
markers of clinical and functional outcomes in advanced cancer
patients. Support Care Cancer. 2013;21:3261-3270.
17. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia: European
consensus on definition and diagnosis: report of the European
Working Group on Sarcopenia in Older People. Age Ageing. 2010;
39:412-423.
18. Leong DP, Teo KK, Rangarajan S, et al. Prognostic value of grip
strength: findings from the Prospective Urban Rural Epidemiology
(PURE) study. Lancet. 2015;386:266-273.
19. Tyrovolas S, Koyanagi A, Olaya B, et al. Factors associated with
skeletal muscle mass, sarcopenia, and sarcopenic obesity in older
adults: a multi-continent study. J Cachexia Sarcopenia Muscle. 2016;
7:312-321.
20. Yoo JI, Choi H, Ha YC. Mean hand grip strength and cut-off value
for sarcopenia in Korean adults using KNHANES VI. J Korean Med
Sci. 2017;32:868-872.
21. Sayer AA. Sarcopenia. BMJ. 2010;341:c4097.
22. Roberts HC, Denison HJ, Martin HJ, et al. A review of the mea-
surement of grip strength in clinical and epidemiological studies:
towards a standardised approach. Age Ageing. 2011;40:423-429.
23. Yang M, Hu X, Wang H, Zhang L, Hao Q, Dong B. Sarcopenia
predicts readmission and mortality in elderly patients in acute care
wards: a prospective study. J Cachexia Sarcopenia Muscle. 2017;8:
251-258.
24. Newman AB, Kupelian V, Visser M, et al. Strength, but not muscle
mass, is associated with mortality in the health, aging and body
composition study cohort. J Gerontol A Biol Sci Med Sci. 2006;61:
72-77.
25. Ong HL, Abdin E, Chua BY, et al. Hand-grip strength among older
adults in Singapore: a comparison with international norms and
associative factors. BMC Geriatr. 2017;17:176.
26. Mendes J, Amaral TF, Borges N, et al. Handgrip strength values of
Portuguese older adults: a population based study. BMC Geriatr.
2017;17:191.
27. Alkahtani SA. A cross-sectional study on sarcopenia using different
methods: reference values for healthy Saudi young men. BMC Mus-
culoskelet Disord. 2017;18:119.
28. Leong DP, Teo KK, Rangarajan S, et al. Reference ranges of hand-
grip strength from 125,462 healthy adults in 21 countries: a pro-
spective urban rural epidemiologic (PURE) study. J Cachexia
Sarcopenia Muscle. 2016;7:535-546.
29. Chen LK, Liu LK, Woo J, et al. Sarcopenia in Asia: consensus
report of the Asian Working Group for Sarcopenia. J Am Med Dir
Assoc. 2014;15:95-101.
30. Reijnierse EM, de Jong N, Trappenburg MC, et al. Assessment of
maximal handgrip strength: how many attempts are needed?
J Cachexia Sarcopenia Muscle. 2017;8:466-474.
Original Article
1506 Cancer April 1, 2018
